In the present study, we found that ΔTLG was a better predictor than ΔSUVmax of nivolumab efficacy, which is consistent with some previous studies on the ability of early phase PET to predict the response to immune-checkpoint inhibitor treatment.20 43 This finding may reflect heterogeneity in tumor infiltration of inflammatory cells in response to nivolumab treatment, which, in turn, may depend on the heterogeneity of tumor PD-L1 expression. Here, CD274 is linked to neoplasm.